Base Metals Investing Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
Base Metals Investing Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Base Metals Investing Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
Base Metals Investing Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer's Disease
